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Extended Spectrum ß Lactamases in Enterobacteriaceae
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Department of Pathology, Aga Khan University, Karachi.

Abstract
Objective: To compare double disc approximation and combined disc method for their ability to detect extended
spectrum b lactamase (ESBL) production in enterobacteriaceae and determine the percentage of isolates which
are falsely reported as sensitive in absence of ESBL detection, in a clinical microbiology laboratory of a tertiary
care hospital between September - October 2002.
Methods: Selected isolates were identified according to standard biochemical tests. Disc susceptibility tests
were performed according to NCCLS. ESBL detection by combined disc {cefotaxime (30ug) versus cefotaxime
plus clavulanate (30+10 ug)} was compared with detection using double discs {amoxy-clavulanic acid (20+10 ug)
and aztreonam (30ug) applied 10 mm apart}. Results were interpreted according to NCCLS and analysed on
SPSS version 10.
Results: ESBL production was detected in 140 (30%) isolates by combined disc method and 139 (29.5%) by
double disc method. There was no significant difference between two methods. Of the ESBL positive isolates
41(29%) gave zone diameters that were within the sensitivity range cutoff and would have been falsely reported
as being beta lactam sensitive in absence of ESBL detection.
Conclusion: ESBL detection should be routinely performed in clinical laboratories as false reporting would result
in treatment failure despite in vitro sensitivity. No difference was found between the combined disc and double
disc methods hence either of two could be used (JPMA 53:534;2003).

Introduction
Extended-spectrum ß-Lactamase (ESBL) producing
organisms are a major problem in the area of infectious
disease1 after discovery in 1983.2,3 These ß-Lactamases can
be produced by a variety of Enterobacteriaceae; however,
the most common ESBL-producing organisms are
Klebsiella species, and Escherichia coli.4,5 These organisms
confer resistant to all ß-Lactam antibiotics except
cephamycins and carbapenems.4,6,7 In addition, ESBLproducing organisms are frequently resistant to many other
classes of antibiotics; including aminoglycosides and
fluoroquinolones4,8 thus treatment of these infections is
often a therapeutic challenge. ESBL arise by mutations in
genes of plasmid mediated beta lactamases (especially TEM
and SHV enzymes).8 A second type of transmissible
resistance arises from plasmid acquisition of a
chromosomal amp C gene providing resistance to
cephamycins as well.9
The frequency of ESBL-producing organisms differs
significantly by geographic location.10-12 The SENTRY
surveillance program reported the frequency of ESBLproducing K. pneumoniae as 45% in Latin America versus
7% in the United States.10 Although considerable variation
exists in the U.S., with a surveillance study of 15 hospitals
in Brooklyn, New York, reporting that 34% of their K.
pneumoniae produce ESBL.11 Frequency of ESBL
producing E. coli at hospitals in the SENTRY surveillance
program was much lower, 1-8%.10 In Pakistan, a study
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performed in Islamabad shows a prevalence of 48% in
nosocomial isolates.13 Another study from Rawalpindi
reported 35% ESBL detection in nosocomial isolates.14
Detection of ESBL is challenging for the clinical
microbiology laboratory.15 Its presence in the bacterial cell
does not always produce a resistant phenotype; some ESBL
isolates may appear susceptible to third-generation
cephalosporins in vitro. Failure of either MIC or disc test
alone to accurately detect the presence of an ESBL has been
well documented.16,17 A proficiency testing project for
clinical laboratories participating in the National
Nosocomial Infections Surveillance System indicated that
as many as 58% of laboratories failed to detect and report
ESBL isolates correctly.18 In some studies, 37% of ESBL
producing organisms were misreported19 whereas in another
study only 7 out of 38 laboratories correctly identified these
organisms.20 These data suggest that improvements in the
ability of clinical laboratories to detect ESBLs are needed as
all ESBL producing organisms should be reported as being
resistant to all penicillins, cephalosporins and aztreonam.21
National Committee for Clinical Laboratory
Standards (NCCLS) and British Society for Antimicrobial
and Chemotherapy (BSAC) have made a standardized
criterion for screening, confirmatory testing and reporting
for these organisms.21,22 Several ESBL detection test have
been proposed based on Kirby Bauer disc diffusion
methodology such as the double disc approximation test23
combined disc method22 and three-dimensional test.24 In
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addition, MIC based methods in which dilution tests are
performed.25 Several commercial tests (Etest ESBL strips)
as well as automated systems (Vitek) are also available for
detection of ESBL.26 None of the tests for phenotypic
detection of ESBL are 100% sensitive or specific, however
double disc approximation test, combined disc method and
broth dilution MIC method are the easiest and cost effective
methods for use by many clinical laboratories.26

positive isolates, 41/140(29%) gave zone diameters with
cefuroxime, cefixime, cefotaxime and aztreonam that were
within the sensitivity range cutoff and would have been
falsely reported as being beta lactam sensitive in absence of
ESBL detection (Figure 2).

Detection of ESBL was initially performed by
double disc approximation test in our laboratory, however
there were person-to-person variation in the interpretation
of results. We therefore, conducted a study comparing
double disc approximation and combined disc method for
the detection of ESBL.

Material and Methods
The study was done in a 550-bed tertiary care
hospital located in Karachi, Pakistan. The clinical
microbiology laboratory receives samples of patients
presenting to the hospital as well as outside referrals from
other hospitals, clinics and general practitioners across
the city.

Figure 1. Frequency of ESBL production within individual organism. % isolates represent ESBL
positive isolates within individual organism/Total isolates of that organism.

In this comparative study, samples were taken of
patients seen at the AKUH, or those referred from other
hospitals, clinics and general practitioners across the city.
Laboratory Methods
All urinary specimens growing members of the
family Enterobacteriaceae. These isolates were identified by
routine biochemical tests.27 Disc susceptibility tests were
performed by criteria according to NCCLS21 using Mueller
Hinton agar (Oxoid). ESBL detection was done by
combined disc method using cefotaxime (30ug) versus
cefotaxime plus clavulanate (30+10 ug) (Oxoid) according
to NCCLS criteria.21 Double disc method was performed by
using disc containing co-amoxiclavulanic acid (20+10 ug)
and aztreonam applied 10 mm apart.22
Data analysis was done using SPSS version 10.
Frequencies were calculated by using descriptive statistics
and expressed as percentages and rate.

Results
During the study period 471 isolates were identified
as Enterobacteriaceae. Frequent isolates were E.coli (74%),
K. pneumoniae(13%), Enterobacter sp. (9%), Proteus sp.
(3%). ESBL production was detected in 140 (30%) isolates
by combined disc method and 139 (29.5%) by double disc
method. No significant difference was found between the
two methods. ESBL production by the organisms studied is
shown in Figure 1 exhibiting that frequency of ESPL
production was highest in Enterobacter with 34% of 41
Enterobacter tested being ESBL positive. Of the ESBL
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Figure 2. Frequency of isolates that could have been falsely reported to cefotaxime, cefixime,
cefuroxime and aztreonam in absence of ESBL detection (n=140).

Discussion
Detection of ESBL is a major challenge for the
clinical microbiology laboratory15 as its detection has major
impact on therapy. Moreover, presence of an ESBL also has
significant infection control implications.26
We have compared two methods for ESBL detection
based on Kirby Bauer disc diffusion methodology. Both of
these methods were found to be equivalent in detection of
ESBL producing isolates. However in the double disc
approximation method distance of disc placement is not
standardized and it has been suggested that reducing the
distance between two discs could increase sensitivity of this
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method.23 Combined disc method is a recently developed
method with ability to detect presence of ESBL.28 A study
reported by Zali et al29 have documented sensitivity of double
discs with ceftazidime plus clauvulanic acid as being 86%
and with cefotaxime plus clauvulanic acid as being 65% and
recommended use of both ceftazidime and cefotaxime
combinations to increase the sensitivity upto 93%.29
Our results show that in the absence of ESBL
detection 29% of isolates would have been reported as
being falsely sensitive with cefuroxime, cefixime,
cefotaxime and aztreonam. Livermore et all have reported
that 37% of ESBL producing organisms were misreported
in their study.19 A study conducted by World Health
Organization using disc diffusion technique found that 5.4%
of laboratories found an ESBL producing strain to be
susceptible to all cephalosporins.30
Double disc method needs two discs which are part
of routine sensitivity in most laboratories, whereas
combined disc method needs only one extra disc in the
regular testing battery. Therefore expense of determination
of ESBL is minimal. However as use of double disc method
needs accurate distance between two discs so there is a need
of precision and person to person variation could occur.
We therefore, recommend that determination of
ESBL production is necessary to prevent misreporting and
hence treatment failure. This detection could be done by
either of the two methods, as both of these methods have
found to be simple as well as cost effective.
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Use of Intravenous anti-D in patients with refractory and relapsed Immune
Thrombocytopenic Purpura
R. Sajid, S. N. Adil, Z. Fadoo, S. Sabir, M. Khurshid
Department of Pathology, The Aga Khan University, Karachi.

Abstract
Objective: To determine the response to IV anti-D and its comparison with splenectomy as second line therapy
in refractory and relapsed cases of ITP, in the Aga Khan University Hospital, Karachi.
Methods: A total of 23 patients with chronic ITP were treated with either anti-D or splenectomy as second line
treatment. The patients were assessed for time to achieve a response to second line treatment, duration of
response and adverse events.
Results: There were 12 patients in the anti-D group and 11 in the splenectomy group. The mean platelet count
at presentation was 9,000/cumm. The mean age was 8.9 years and 13.0 years and the male to female ratio was
1:1 and 1:1.2 in anti-D and splenectomy group respectively. 54.5% of the patient in the anti-D group responded
compared to 81.8% in the splenectomy group. Median time to achieve a response was 7 days in the anti-D group
and 1 day in the splenectomy group. Mean time to relapse was 87.8 days in the anti-D group and 55.4 days in
the splenectomy group. No adverse events were recorded for any of the infusions of anti-D and none of the
patients had more than 0.5 gm /dl fall in the hemoglobin level following anti-D infusion.
Conclusion: It was thus concluded that Anti-D is a relatively safe, convenient and effective therapy for chronic
ITP and can be used as a splenectomy sparing agent when treatment is clinically indicated (JPMA 53:537;2003).

Introduction
Immune thrombocytopenic purpura (ITP) is an
acquired disease of children and adults defined by a low
platelet count in the absence of other clinically apparent
causes of thrombocytopenia.1 It is principally a disorder of
increased platelet destruction caused by antiplatelet
antibodies.
In 1983 Salama et al reported platelet responses in
three of six Rh (D) positive patients treated with 400 to
2500 ug of anti-D (2).Anti-D is a plasma derived
immunoglobulin prepared from donors selected for a high
titer of Rho (D) antibody. The investigators suggested that
the rise in platelet count is due to competitive inhibition of
the macrophage binding of platelets by preferential
sequestration of immunoglobulin coated red blood cells.2
Important observations from published reports
include evidence of a dose response relationship,
reproducibility of responses, and efficacy of anti-D in Rh
(D) positive but not in Rh (D) negative subjects. Similarly
splenectomized patients had minimal or no responses.3 The
lower cost of anti-D plus the ease of administration make
anti-D therapy an attractive option as splenectomy sparing
therapy and as maintenance therapy in patients with chronic
ITP.4

Patients and Methods
This was a case series study which was carried out
from January 2000 to October 2002.
This study was conducted upon diagnosed patients
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with Immune Thrombocytopenic Purpura. All patients of
ITP received Anti-D were included in one group and
patients who underwent splenectomy were included in the
second group. Patients with established diagnosis of ITP
were included in the study. All patients who had persistently
low platelet counts for at least six months , were blood
group Rh positive (anti-D group) had not undergone
splenectomy and were not receiving other forms of therapy
were included in the study. Post splenectomy patients and
patients with blood group other than Rh positive were
excluded.
Patients were eligible for inclusion if they had a
diagnosis of acute or chronic ITP, had not undergone
splenectomy, their blood group was Rh positive (anti-D
group). All 23 patients included in the study fulfilled the
criteria mentioned above. All patients were analyzed for
demographic features including age, sex, age at the time of
diagnosis, clinical features at presentation, response to
initial treatment, rise in platelet counts following second
line treatment (IV anti-D) and persistence of response for 3
months. Response was defined as an increase in platelet
count to >50,000/cumm or doubling of pretreatment platelet
counts. Any adverse events with anti-D or splenectomy
were also recorded.
Anti-D (WinRho) was given at a dose of 50mg/kg.
The anti-D preparation was diluted in physiologic normal
saline and infused intravenously during a 15-30 minute
period on an outpatient basis. Patients were followed at
weekly intervals and any adverse events were recorded.
Complete blood count was performed at each outpatient
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